Uveitis Treatment Market size was valued at 581 million in 2021 and is expected to reach 857 million by 2028, at a CAGR of 5.7% during the forecast period 2022 to 2028. Market players are developing novel molecules that can treat uveitis conditions in order to enhance their sales revenue. Companies are focusing on the development of the various drugs in the treatment of the uveitis. For instance, Aurinia Pharmaceuticals Inc. developing Luvenia, a calcineurin inhibitor for the treatment of noninfectious uveitis. Recently it has completed its phase-II clinical trials. Similarly, other pipeline drugs such as EMEA, DE-109, Gevokizumab, Peptide B27PD are being developed by different companies.

https://www.precisionbusinessinsights.com/market-reports/global-uveitis-treatment-market